Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome
Purpose. Injection of anti-VEGF antibody into the vitreous body is a well-established treatment for ischemic central retinal vein occlusion (CRVO) associated macular edema. Various treatment regimens regarding the timing, number, and frequency of injections have been proposed. Methods. We reviewed t...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2013/974670 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558347758338048 |
|---|---|
| author | Joseph Pikkel Otzem Chassid Yumna Busool Ward Srour Adi Sharabi-Nov Itzchak Beiran |
| author_facet | Joseph Pikkel Otzem Chassid Yumna Busool Ward Srour Adi Sharabi-Nov Itzchak Beiran |
| author_sort | Joseph Pikkel |
| collection | DOAJ |
| description | Purpose. Injection of anti-VEGF antibody into the vitreous body is a well-established treatment for ischemic central retinal vein occlusion (CRVO) associated macular edema. Various treatment regimens regarding the timing, number, and frequency of injections have been proposed. Methods. We reviewed the medical records of 68 patients treated by intravitreal bevacizumab (Avastin) injections for macular edema due to CRVO. We examined final visual acuity six months following the last injection in relation to injection policy (one primary injection followed by subsequent injections based on anatomical response versus a prescheduled protocol of one injection per month for the first 3 months) and in relation to the time lapsing from CRVO diagnosis to the first injection. Results. Mean visual acuity improved more for patients treated by a protocol of 3 prescheduled injections than for those treated with one primary injection. Improvement in mean visual acuity was greater for patients who received their first injection within the first month than those treated after 3 months (P<0.01). Conclusion. A protocol of three prescheduled injections of bevacizumab, starting within one month of a CRVO event, was associated with better visual outcome compared to single injection and/or treatment starting more than 3 months following the time of diagnosis. |
| format | Article |
| id | doaj-art-d663418b2b8a4ac2bada1665787bbbfe |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-d663418b2b8a4ac2bada1665787bbbfe2025-02-03T01:32:41ZengWileyJournal of Ophthalmology2090-004X2090-00582013-01-01201310.1155/2013/974670974670Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual OutcomeJoseph Pikkel0Otzem Chassid1Yumna Busool2Ward Srour3Adi Sharabi-Nov4Itzchak Beiran5Department of Ophthalmology, Ziv Medical Center, Safed, IsraelDepartment of Ophthalmology, Ziv Medical Center, Safed, IsraelDepartment of Ophthalmology, Ziv Medical Center, Safed, IsraelDepartment of Ophthalmology, Ziv Medical Center, Safed, IsraelResearch Wing, Ziv Medical Center, Safed, Israel and Tel-Hai Academic College, IsraelDepartment of Ophthalmology, Rambam Medical Center, Haifa, IsraelPurpose. Injection of anti-VEGF antibody into the vitreous body is a well-established treatment for ischemic central retinal vein occlusion (CRVO) associated macular edema. Various treatment regimens regarding the timing, number, and frequency of injections have been proposed. Methods. We reviewed the medical records of 68 patients treated by intravitreal bevacizumab (Avastin) injections for macular edema due to CRVO. We examined final visual acuity six months following the last injection in relation to injection policy (one primary injection followed by subsequent injections based on anatomical response versus a prescheduled protocol of one injection per month for the first 3 months) and in relation to the time lapsing from CRVO diagnosis to the first injection. Results. Mean visual acuity improved more for patients treated by a protocol of 3 prescheduled injections than for those treated with one primary injection. Improvement in mean visual acuity was greater for patients who received their first injection within the first month than those treated after 3 months (P<0.01). Conclusion. A protocol of three prescheduled injections of bevacizumab, starting within one month of a CRVO event, was associated with better visual outcome compared to single injection and/or treatment starting more than 3 months following the time of diagnosis.http://dx.doi.org/10.1155/2013/974670 |
| spellingShingle | Joseph Pikkel Otzem Chassid Yumna Busool Ward Srour Adi Sharabi-Nov Itzchak Beiran Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome Journal of Ophthalmology |
| title | Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome |
| title_full | Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome |
| title_fullStr | Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome |
| title_full_unstemmed | Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome |
| title_short | Bevacizumab for CRVO Associated CME: Effect of Timing and Frequency of Injections on Final Visual Outcome |
| title_sort | bevacizumab for crvo associated cme effect of timing and frequency of injections on final visual outcome |
| url | http://dx.doi.org/10.1155/2013/974670 |
| work_keys_str_mv | AT josephpikkel bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome AT otzemchassid bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome AT yumnabusool bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome AT wardsrour bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome AT adisharabinov bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome AT itzchakbeiran bevacizumabforcrvoassociatedcmeeffectoftimingandfrequencyofinjectionsonfinalvisualoutcome |